Alpha Capital reveals 2.223% passive stake in Qualigen Therapeutics (QLGN)
Alpha Capital Anstalt has filed Amendment No. 2 to Schedule 13G for Qualigen Therapeutics (QLGN).
Rhea-AI Filing Summary
Alpha Capital Anstalt has filed Amendment No. 2 to Schedule 13G for Qualigen Therapeutics (QLGN).
- Beneficial ownership: 36,434 common shares.
- Ownership percentage: 2.223 % of the 1,635,475 shares outstanding as of 18 Jul 2025.
- Voting & dispositive power: Sole power over all reported shares; no shared power.
- Filer details: Liechtenstein entity, address Altenbach 8, FL-9490 Vaduz.
- Purpose: Certified as a passive investment with no intent to influence control.
The update simply records Alpha Capital’s sub-5 % stake; it carries limited strategic or valuation implications for QLGN shareholders.
Positive
- None.
Negative
- None.
Insights
TL;DR: Filing shows Alpha Capital’s passive 2.223 % stake in QLGN; below 5 % threshold, minimal market impact.
The amendment confirms Alpha Capital Anstalt now holds 36,434 QLGN shares with sole voting and dispositive authority. At 2.223 % of outstanding equity, the position is well under the 5 % level that typically signals potential influence. The certification of passive intent further reduces governance significance. Absent evidence of recent buying or selling velocity, the disclosure is routine and should not materially affect liquidity, float, or strategic optionality. Therefore, investor reaction is expected to be muted.
FAQ
What percentage of QLGN’s outstanding stock does this represent?
Is Alpha Capital seeking to influence Qualigen Therapeutics’ management?
Why was an amendment to Schedule 13G filed?
AI-generated analysis. How Rhea-AI works. Not financial advice.